Granulosa cell tumors of the ovary: a clinicopathologic and immunohistochemical study of 21 cases

Purpose: To further study the clinicopathologic and immunohistochemical features of ovarian granulosa cell tumors (GCTs). Methods: We retrospectively studied all cases of GCTs diagnosed in our laboratory over the last 10-year period. Immunohistochem-istry for inhibin, vimentin, cytokeratin, Ki-67 and p53 was performed on archival paraffin blocks. Pathologic and immunohistochemical findings were correlated with the clinical records of the patients. Results: Twenty-one cases (15 of the adult and 6 of the juvenile type) were retrieved. All patients were FIGO Stage I at the time of diagnosis. Recurrent disease was detected in four patients (19 %) during a median follow-up of 36 months (range 2-26 years). Pathology revealed a concomitant thecacell component in three cases, a Sertoli-Leydig component in one case, and a thecoma in one case. Archival tissue material was available in 12 cases. Immunohistochemistry was positive for: β-inhibin in 12/12 cases (100%), vimentin in 11/12 cases (91.7%), cytokeratin in 3/12 cases (25%), CD34 in 0 cases (0%), and p53 in 2/12 cases (16.7%). The Ki-67 index was < 5% in 12/12 cases (100%). No significant correlations were observed between the pathologic and immunohistochemical parameters examined and the clinical outcome. Conclusions: Despite the relatively indolent nature and favorable prognosis of most GCTs, late recurrences are not a rare event even in Stage I patients, necessitating a close and long-term follow-up. The identification of novel prognostic markers, in addition to our traditional staging parameters such as clinical staging, is needed in order to more accurately predict probabilities of recurrence in these patients.

Adult; Juvenile; Granulosa cell tumor; Ovary.

[1] Rosai J., Ackerman L.V.: “Ovary”. In: Rosai J. (ed), Surgical Pathology. Edinburgh, Mosby, 2004, 1649.

[2] Schumer S. T., Cannistra S.A.: “Granulosa cell tumor of the ovary”. J. Clin. Oncol., 2003, 21, 1180.

[3] Gusberg S.B., Kardon P.: “Proliferative endometrial response to thecagranulosa cell tumors”. Am. J. Obstet Gynecol., 1971, 111, 633.

[4] Fox H., Agrawal K., Langley F.A.: “A clinicopathologic study of 92 cases of granulosa cell tumor of the ovary with special reference to factors influencing prognosis”. Cancer, 1975, 35, 231.

[5] Bjorkholm E., Silfversward C.: “Prognostic factors in granulosa cell tumors”. Gynecol. Oncol., 1981, 11, 261.

[6] Evans A.T., Gaffey T.A., Malkasian G.D., Annegers G.F.: “Clinicopathologic review of 118 granulosa and 82 theca cell tumors”. Obstet. Gynecol., 1980, 55, 231.

[7] Malmstrom H., Hogberg T., Risberg B., Simonsen E.: “Granulosa cell tumors of the ovary: Prognostic factors and outcome”. Gynecol. Oncol., 1994, 52, 50.

[8] Lauszus F.F., Peterson A.C., Greisen J., Jakobsen A.: “Granulosa cell tumor of the ovary: a population-based study of 37 women with stage I disease”. Gynecol. Oncol., 2001, 81, 456.

[9] Miller B.E., Barron B.A., Wan J.Y., Delmore J.E., Silva E.G.: “Prognostic factors in adult granulose cell tumor of the ovary”. Cancer, 1997, 79, 1951.

[10] Young R.H., Scully R.E.: “Ovarian sex cord-stromal tumors. Recent progress”. Int. J. Gynecol. Pathol., 1982, 1, 101.

[11] Stuart G.C., Dawson L.M.: “Update on granulosa cell tumours of the ovary”. Curr. Opin. Obstet. Gynecol., 2003, 15, 33.

[12] Cronje H. S., Niemand I., Bam R.H., Woodruff J.D.: “Review of the granulosatheca cell tumors from the emil Novak ovarian tumor registry”. Am. J. Obstet. Gynecol., 1999, 180, 323.

[13] Case records of the Massachusetts General Hospital: “Weekly clinicopathological exercises. Case 10-1995. A 56-year-old woman with abdominal pain, anemia and a pelvic mass”. N. Engl. J. Med., 1995, 332, 876.

[14] Villella J., Herrmann F.R., Kaul S., Lele S., Marchetti D., Natiella J. et al.: “Clinical and pathological predictive factors in women with adult-type granulosa cell tumor of the ovary”. Int. J. Gynecol. Pathol., 2007, 26, 154.

[15] Piura B., Nemet B., Yanai-Inbar I., Cohen Y., Glezerman M.: “Granulosa cell tumor of the ovary: a study of 18 cases”. J. Surg. Oncol., 1994, 55, 71.

[16] Hines J.F., Khalifa M.A., Moore J.L., Fine K.P., Lage J.M., Barnes W.A.: “Recurrent granulosa cell tumor of the ovary 37 years after initial diagnosis: a case report and review of the literature”. Gyne col. Oncol., 1996, 60, 484.

[17] Lappohn R.E., Burger H.G., Bouma J., Bangah M., Krans M., de Bruijn H.W.: “Inhibin as a marker for granulosacell tumors”. N. Engl. J. Med., 1989, 321, 790.

[18] Robertson D.M., Stephenson T., Pruysers E., Burger H.G., McCloud P., Tsigos A. et al.: “ Inhibin/activins as diagnostic markers for ovarian cancer”. Mol. Cell. Endocrinol., 2002, 191, 97.

[19] King L.A., Okagaki T., Gallup D.G., Twiggs L.B., Messing M.J., Carson L.F.: “Mitotic count, nuclear atypia, and immunohistochemical determination of Ki-67, c-myc, p21-ras, c-erbB2 and p53 expression in granulosa cell tumors of the ovary: mitotic count and Ki-67 are indicators of poor prognosis”. Gynecol. Oncol., 1996, 61, 227.

[20] Costa M.J., Walls J., Ames P., Roth L.M.: “Transformation in recurrent ovarian granulosa cell tumors: Ki-67(MIB-1) and p53 immunohistochemistry demonstrates a possible molecular basis for the poor histopathologic prediction of clinical behavior”. Hum. Pathol., 1996, 27, 274.

[21] Klemi P.J., Joensuu H., Salmi T.: “Prognostic value of flow cytometric DNA content analysis in granulosa cell tumor of the ovary”. Cancer, 1990, 65, 1189.

[22] Haba R., Miki H., Kobayashi S., Ohmori M.: “Combined analysis of flow cytometry and morphometry of ovarian granulosa cell tumor”. Cancer, 1993, 72, 3258.

[23] Auranen A., Sundstrom J., Ijas J., Grenman S.: “Prognostic factors of ovarian granulosa cell tumor: a study of 35 patients and review of the literature” . Int. J. Gynecol. Cancer, 2007, 17, 1011.